Literature DB >> 1834013

Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.

B Fantin1, R Leclercq, M Arthur, J Duval, C Carbon.   

Abstract

Emergence of vancomycin-resistant strains among enterococci raises a new clinical challenge. Rabbits with aortic endocarditis were infected with Enterococcus faecium BM4172, a clinical strain resistant to low levels of vancomycin (MIC, 16 micrograms/ml) and susceptible to teicoplanin (MIC, 1 micrograms/ml), and against its susceptible variant E. faecium BM4172S obtained in vitro by insertional mutagenesis (MICs, 2 and 0.5 micrograms/ml, respectively). Control animals retained 8 to 10.5 log10 CFU/g of vegetation. We evaluated in this model the efficacy of vancomycin (30 mg/kg of body weight; mean peak and trough serum levels, 27 and 5 micrograms/ml, respectively), teicoplanin (standard dose, 10 mg/kg; mean peak and trough levels, 23 and 9 micrograms/ml, respectively; and high dose, 20 mg/kg; mean peak and trough levels, 63 and 25 micrograms/ml, respectively), gentamicin (6 mg/kg; mean peak and trough levels, 8.6 and less than 0.1 micrograms/ml, respectively), alone or in combination, given every 12 h intramuscularly for 5 days. Teicoplanin standard dose was as active as vancomycin against both strains. Vancomycin was not effective against E. faecium BM4172 but was highly effective against E. faecium BM4172S (7.5 +/- 1.1 log10 CFU/g of vegetation versus 4.9 +/- 1.0 log10 CFU/g of vegetation for vancomycin against E. faecium BM4172 and E. faecium BM4172S, respectively; P = 0.0012). A high dose of teicoplanin was more effective than vancomycin against E. faecium BM4172 (4.4 +/- 1.8 log10 CFU/g of vegetation versus 7.5 +/- 1.1 log10 CFU/g of vegetation for teicoplanin high dose and vancomycin, respectively; P less than 0.05). Against E. faecium BM4172 glycopeptide-gentamicin combinations were the most effective regimens in vitro and in vivo (2.8 +/- 0.7 and 3.5 +/- 1.3 log10 CFU/g of vegetation for vancomycin plus gentamicin and teicoplanin standard dose plus gentamicin, respectively; P < 0.05 versus single-drug regimens). We concluded that high-dose teicoplanin or the combination of a glycopeptide antibiotic plus gentamicin was effective against experimental infection due to E. faecium with low-level resistance to vancomycin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834013      PMCID: PMC245220          DOI: 10.1128/AAC.35.8.1570

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Microbiological properties of teicoplanin.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

Review 2.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

3.  Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.

Authors:  B Fantin; B Pangon; G Potel; F Caron; E Vallée; J M Vallois; J Mohler; A Buré; A Philippon; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.

Authors:  J D Yao; C Thauvin-Eliopoulos; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide.

Authors:  Y Nivoche; A Contrepois; A C Cremieux; C Carbon
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

7.  The antibacterial action of vancomycin.

Authors:  C Watanakunakorn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

8.  Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; M Weber; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

View more
  16 in total

1.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.

Authors:  S Dutka-Malen; S Evers; P Courvalin
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.

Authors:  Carlos A Rodriguez; Maria Agudelo; Javier M Gonzalez; Omar Vesga; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

6.  Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis.

Authors:  M Lafaurie; B Perichon; A Lefort; C Carbon; P Courvalin; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Increasing problems in the therapy of enterococcal infections.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

8.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.

Authors:  M L Sanchez; R P Wenzel; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.